Gender-dependent effect of L-NAME on polycystic kidney disease in Han: SPRD rats

Izumi Yoshida, Rosemary Bengal, Vicente Torres

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

To determine whether the renal nitric oxide (NO) system has a role in the pathogenesis of polycystic kidney disease (PKD) in Han:Sprague-Dawley (SPRD) rats, the NO synthase (NOS) inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), 70 mg/L, or L-arginine, 0.5 g/L, was administered to heterozygous diseased (cy/+) and homozygous normal animals. Urine nitrate and nitrite excretion was reduced by L-NAME treatment and, in the male cy/+ rats, increased by L-arginine administration. The administration of L-NAME significantly increased blood pressure in all groups, whereas L-arginine had no effect. L-NAME and L-arginine had a modest but significant overall effect on the severity of cystic disease in male rats, reflected by relative kidney weights and cyst volume densities. This effect was gender dependent because it was not observed in female animals. The administration of L-NAME resulted in a significant increase in plasma creatinine concentration of the cy/+ rats, which was more marked in male than female animals. These observations support the recently reported gender differences in the renal NO system and a small role for NO synthesis that can be inhibited by L-NAME in the pathogenesis of PKD in Han:SPRD rats. These observations do not exclude a more important role for the endogenous renal NO production in the pathogenesis of PKD in view of a recent report of a major NOS resistant to conventional inhibitors in the rat kidney. (C) 2000 by the National Kidney Foundation, Inc.

Original languageEnglish (US)
Pages (from-to)930-936
Number of pages7
JournalAmerican Journal of Kidney Diseases
Volume35
Issue number5
StatePublished - 2000

Fingerprint

Polycystic Kidney Diseases
NG-Nitroarginine Methyl Ester
Sprague Dawley Rats
Arginine
Kidney
Nitric Oxide
Nitric Oxide Synthase
Nitrites
Nitrates
Cysts
Creatinine
Urine
Blood Pressure
Weights and Measures

Keywords

  • Han:Sprague-Dawley (SPRD) rat
  • L-arginine
  • N(G)-nitro-L-arginine methyl ester (L-NAME)
  • Nitric oxide (NO)
  • Polycystic kidney disease (PKD)

ASJC Scopus subject areas

  • Nephrology

Cite this

Gender-dependent effect of L-NAME on polycystic kidney disease in Han : SPRD rats. / Yoshida, Izumi; Bengal, Rosemary; Torres, Vicente.

In: American Journal of Kidney Diseases, Vol. 35, No. 5, 2000, p. 930-936.

Research output: Contribution to journalArticle

@article{81b80dcdfa034c91bbad2e445f55fae5,
title = "Gender-dependent effect of L-NAME on polycystic kidney disease in Han: SPRD rats",
abstract = "To determine whether the renal nitric oxide (NO) system has a role in the pathogenesis of polycystic kidney disease (PKD) in Han:Sprague-Dawley (SPRD) rats, the NO synthase (NOS) inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), 70 mg/L, or L-arginine, 0.5 g/L, was administered to heterozygous diseased (cy/+) and homozygous normal animals. Urine nitrate and nitrite excretion was reduced by L-NAME treatment and, in the male cy/+ rats, increased by L-arginine administration. The administration of L-NAME significantly increased blood pressure in all groups, whereas L-arginine had no effect. L-NAME and L-arginine had a modest but significant overall effect on the severity of cystic disease in male rats, reflected by relative kidney weights and cyst volume densities. This effect was gender dependent because it was not observed in female animals. The administration of L-NAME resulted in a significant increase in plasma creatinine concentration of the cy/+ rats, which was more marked in male than female animals. These observations support the recently reported gender differences in the renal NO system and a small role for NO synthesis that can be inhibited by L-NAME in the pathogenesis of PKD in Han:SPRD rats. These observations do not exclude a more important role for the endogenous renal NO production in the pathogenesis of PKD in view of a recent report of a major NOS resistant to conventional inhibitors in the rat kidney. (C) 2000 by the National Kidney Foundation, Inc.",
keywords = "Han:Sprague-Dawley (SPRD) rat, L-arginine, N(G)-nitro-L-arginine methyl ester (L-NAME), Nitric oxide (NO), Polycystic kidney disease (PKD)",
author = "Izumi Yoshida and Rosemary Bengal and Vicente Torres",
year = "2000",
language = "English (US)",
volume = "35",
pages = "930--936",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Gender-dependent effect of L-NAME on polycystic kidney disease in Han

T2 - SPRD rats

AU - Yoshida, Izumi

AU - Bengal, Rosemary

AU - Torres, Vicente

PY - 2000

Y1 - 2000

N2 - To determine whether the renal nitric oxide (NO) system has a role in the pathogenesis of polycystic kidney disease (PKD) in Han:Sprague-Dawley (SPRD) rats, the NO synthase (NOS) inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), 70 mg/L, or L-arginine, 0.5 g/L, was administered to heterozygous diseased (cy/+) and homozygous normal animals. Urine nitrate and nitrite excretion was reduced by L-NAME treatment and, in the male cy/+ rats, increased by L-arginine administration. The administration of L-NAME significantly increased blood pressure in all groups, whereas L-arginine had no effect. L-NAME and L-arginine had a modest but significant overall effect on the severity of cystic disease in male rats, reflected by relative kidney weights and cyst volume densities. This effect was gender dependent because it was not observed in female animals. The administration of L-NAME resulted in a significant increase in plasma creatinine concentration of the cy/+ rats, which was more marked in male than female animals. These observations support the recently reported gender differences in the renal NO system and a small role for NO synthesis that can be inhibited by L-NAME in the pathogenesis of PKD in Han:SPRD rats. These observations do not exclude a more important role for the endogenous renal NO production in the pathogenesis of PKD in view of a recent report of a major NOS resistant to conventional inhibitors in the rat kidney. (C) 2000 by the National Kidney Foundation, Inc.

AB - To determine whether the renal nitric oxide (NO) system has a role in the pathogenesis of polycystic kidney disease (PKD) in Han:Sprague-Dawley (SPRD) rats, the NO synthase (NOS) inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), 70 mg/L, or L-arginine, 0.5 g/L, was administered to heterozygous diseased (cy/+) and homozygous normal animals. Urine nitrate and nitrite excretion was reduced by L-NAME treatment and, in the male cy/+ rats, increased by L-arginine administration. The administration of L-NAME significantly increased blood pressure in all groups, whereas L-arginine had no effect. L-NAME and L-arginine had a modest but significant overall effect on the severity of cystic disease in male rats, reflected by relative kidney weights and cyst volume densities. This effect was gender dependent because it was not observed in female animals. The administration of L-NAME resulted in a significant increase in plasma creatinine concentration of the cy/+ rats, which was more marked in male than female animals. These observations support the recently reported gender differences in the renal NO system and a small role for NO synthesis that can be inhibited by L-NAME in the pathogenesis of PKD in Han:SPRD rats. These observations do not exclude a more important role for the endogenous renal NO production in the pathogenesis of PKD in view of a recent report of a major NOS resistant to conventional inhibitors in the rat kidney. (C) 2000 by the National Kidney Foundation, Inc.

KW - Han:Sprague-Dawley (SPRD) rat

KW - L-arginine

KW - N(G)-nitro-L-arginine methyl ester (L-NAME)

KW - Nitric oxide (NO)

KW - Polycystic kidney disease (PKD)

UR - http://www.scopus.com/inward/record.url?scp=0034005847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034005847&partnerID=8YFLogxK

M3 - Article

C2 - 10793029

AN - SCOPUS:0034005847

VL - 35

SP - 930

EP - 936

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -